Search This Blog

Monday, March 30, 2020

J&J picks lead Covid-19 vaccine candidate

Johnson & Johnson (NYSE:JNJ) is up 4% premarket on light volume in reaction to its announcement that it has selected a lead COVID-19 vaccine candidate.
A Phase 1 clinical trial should launch in September. The first batches of product could be available for emergency use in early 2021.
It plans to establish new U.S. vaccine manufacturing capabilities and additional capacity ex-U.S.
https://seekingalpha.com/news/3556197-j-and-j-picks-lead-covidminus-19-vaccine-candidate-shares-gain

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.